Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Marc Herant
Exercise with cancer: it’s about more than fitness
Retrospective observational studies very frequently highlight the correlation of various lifestyle characteristics with outcomes, but most of the tim…
- By Jacob Wiesenthal and Tory Wolff
More frequent routine primary care visits for certain higher-risk commercially insured adults are associated with lower net population-level health care costs.…
- By Jacob Wiesenthal and Tory Wolff
A new AJMC study from consulting firm Recon Strategy is the first to show how advanced primary care techniques, previously proven in older Medicare populations, could also deliver substantial savings …
- By Jacob Wiesenthal and Tory Wolff
More frequent routine primary care visits for certain higher-risk commercially insured adults are associated with lower net population-level health care costs.…
- By Martha Deja and Sarah Dolman
Download a PDF of this paper here. A comprehensive slide-deck (including a breakdown by therapeutic area) and a complete list of assets deals are also available; click [datapack] to access.
Ear…
- By Jacob Wiesenthal
Guidelines for breast cancer screening aim to increase early detection and survival. However, diagnostic follow-up relies on provider discretion, leading to variability in subsequent care and total co…
- By Maggie Pickard, Allison Cremer, and Jason Brauner
We explore four hypothesized value drivers of platform-based companies and evaluate the actual value achieved 10-15 years out from initial capital raise. We found that discovery platforms showed the highest lead asset success rates, significantly more out-licensing activity than non-platforms, and accounted for nearly all multi-asset approvals within our cohort. All platform types showed increased survivability and more licensing opportunities.
- By Maggie Pickard and Marc Herant
Merck's acquisition of Verona is the latest in a long line of "revenue acquisitions". How have prior mid-size biopharma revenue acquisitions fared? We found that forecasts at the time of deal are often optimistic, with many transactions missing their projected sales trajectories.
- By Marc Herant
The first porcine kidney transplant (in a live recipient)
It’s been a year, and like many, I have been waiting for the details to be published in the NEJM (where else – especially since this was done …